Sectors & Industries HealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2024)
Top general drug manufacturer stocks in 2024 ranked by overall Zen Score. See the best general drug manufacturer stocks to buy now, according to analyst forecasts for the drug manufacturers - general industry.

Industry: Drug Manufacturers - Gene...

Overview Zen Score Price Valuation Financials Forecast Earnings & Revenue Dividends

Ticker	Company	Market Cap	Dividend Yield	Payout Ratio	Last Dividend	Annual Dividend	Dividend Percentile	Dividend Dropped Count (L10Y)	Ex-dividend Date	Div. Payment Date
JNJ	JOHNSON & JOHNSON	$352.99B	3.28%	31.20%	$1.2400	$4.81	61%	0		2024-06-04
SNY	SANOFI	$124.03B	4.16%	82.10%	$2.0374	$2.04	73%	1		2024-06-06
LLY	ELI LILLY & CO	$779.66B	0.59%	68.80%	$1.3000	$4.86	10%	0		2024-06-10
NVS	NOVARTIS AG	$210.43B	3.66%	51.00%	$3.7772	$3.78	66%	2
GSK	GSK PLC	$90.52B	3.31%	53.30%	$0.3762	$1.48	62%	10		2024-07-11
AZN	ASTRAZENECA PLC	$241.89B	1.86%	70.90%	$0.9850	$1.45	39%	9
BIIB	BIOGEN INC	$32.75B	N/A	0.00%	N/A	N/A	N/A	N/A
ABBV	ABBVIE INC	$284.73B	3.76%	179.80%	$1.5500	$6.06	68%	0
MRK	MERCK & CO INC	$317.97B	2.39%	329.70%	$0.7700	$3.00	49%	0	2024-06-17	2024-07-08
AMGN	AMGEN INC	$164.07B	2.86%	122.70%	$2.2500	$8.76	56%	0		2024-06-07
GILD	GILEAD SCIENCES INC	$80.07B	4.70%	755.00%	$0.7700	$3.02	78%	0	2024-06-14	2024-06-27
OGN	ORGANON & CO	$5.49B	1.31%	13.70%	$0.2800	$0.28	27%	0
GRFS	GRIFOLS SA	$4.92B	N/A	0.00%	$0.4562	N/A	N/A	4
BMY	BRISTOL MYERS SQUIBB CO	$83.29B	5.69%	-75.70%	$0.6000	$2.34	84%	0
PFE	PFIZER INC	$162.40B	5.79%	-3,300.00%	$0.4200	$1.66	84%	0		2024-06-14
SCLX	SCILEX HOLDING CO	$195.69M	N/A	0.00%	N/A	N/A	N/A	N/A
AMRN	AMARIN CORP PLC	$355.40M	N/A	0.00%	N/A	N/A	N/A	N/A
MIRA	MIRA PHARMACEUTICALS INC	$12.09M	N/A	0.00%	N/A	N/A	N/A	N/A

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in Jun 2024?

According to Zen Score, the 3 best general drug manufacturer stocks to buy right now are:

1. Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) is the top general drug manufacturer stock with a Zen Score of 62, which is 26 points higher than the general drug manufacturer industry average of 36. It passed 23 out of 38 due diligence checks and has strong fundamentals. Johnson & Johnson has seen its stock lose -5.41% over the past year, underperforming other general drug manufacturer stocks by -28 percentage points.

Johnson & Johnson has an average 1 year price target of $176.88, an upside of 20.59% from Johnson & Johnson's current stock price of $146.67.

Johnson & Johnson stock has a consensus Buy recommendation according to Wall Street analysts. Of the 8 analysts covering Johnson & Johnson, 37.5% have issued a Strong Buy rating, 25% have issued a Buy, 37.5% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Sanofi (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) is the second best general drug manufacturer stock with a Zen Score of 54, which is 18 points higher than the general drug manufacturer industry average of 36. It passed 19 out of 38 due diligence checks and has strong fundamentals. Sanofi has seen its stock lose -3.9% over the past year, underperforming other general drug manufacturer stocks by -26 percentage points.

Sanofi has an average 1 year price target of $55.00, an upside of 12.18% from Sanofi's current stock price of $49.03.

Sanofi stock has a consensus Hold recommendation according to Wall Street analysts. Of the 1 analyst covering Sanofi, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Eli Lilly & Co (NYSE:LLY)

Eli Lilly & Co (NYSE:LLY) is the third best general drug manufacturer stock with a Zen Score of 51, which is 15 points higher than the general drug manufacturer industry average of 36. It passed 20 out of 38 due diligence checks and has strong fundamentals. Eli Lilly & Co has seen its stock return 91.02% over the past year, overperforming other general drug manufacturer stocks by 69 percentage points.

Eli Lilly & Co has an average 1 year price target of $845.07, an upside of 3.01% from Eli Lilly & Co's current stock price of $820.34.

Eli Lilly & Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 15 analysts covering Eli Lilly & Co, 73.33% have issued a Strong Buy rating, 13.33% have issued a Buy, 13.33% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the general drug manufacturer stocks with highest dividends?

Out of 12 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) has an annual dividend yield of 5.79%, which is 2 percentage points higher than the general drug manufacturer industry average of 3.34%. Pfizer's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Pfizer's dividend has shown consistent growth over the last 10 years.

Pfizer's dividend payout ratio of -3,300% indicates that its high dividend yield might not be sustainable for the long-term.

2. Bristol Myers Squibb Co (NYSE:BMY)

Bristol Myers Squibb Co (NYSE:BMY) has an annual dividend yield of 5.69%, which is 2 percentage points higher than the general drug manufacturer industry average of 3.34%. Bristol Myers Squibb Co's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Bristol Myers Squibb Co's dividend has shown consistent growth over the last 10 years.

Bristol Myers Squibb Co's dividend payout ratio of -75.7% indicates that its high dividend yield might not be sustainable for the long-term.

3. Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) has an annual dividend yield of 4.7%, which is 1 percentage points higher than the general drug manufacturer industry average of 3.34%. Gilead Sciences's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Gilead Sciences's dividend has shown consistent growth over the last 10 years.

Gilead Sciences's dividend payout ratio of 755% indicates that its high dividend yield might not be sustainable for the long-term.

Why are general drug manufacturer stocks up?

General drug manufacturer stocks were up 1.36% in the last day, and up 0.94% over the last week. Gilead Sciences was the among the top gainers in the drug manufacturers - general industry, gaining 0.3% yesterday.

Gilead shares are trading lower after the company's Phase 3 TROPiCS-04 study missed its primary endpoint of overall survival.

What are the most undervalued general drug manufacturer stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued general drug manufacturer stocks right now are:

1. Sanofi (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) is the most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Sanofi has a valuation score of 86, which is 54 points higher than the general drug manufacturer industry average of 32. It passed 6 out of 7 valuation due diligence checks.

Sanofi's stock has dropped -3.9% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -26 percentage points.

2. Gsk (NYSE:GSK)

Gsk (NYSE:GSK) is the second most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Gsk has a valuation score of 71, which is 39 points higher than the general drug manufacturer industry average of 32. It passed 5 out of 7 valuation due diligence checks.

Gsk's stock has gained 33.24% in the past year. It has overperformed other stocks in the general drug manufacturer industry by 11 percentage points.

3. Biogen (NASDAQ:BIIB)

Biogen (NASDAQ:BIIB) is the third most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Biogen has a valuation score of 71, which is 39 points higher than the general drug manufacturer industry average of 32. It passed 5 out of 7 valuation due diligence checks.

Biogen's stock has dropped -24.11% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -46 percentage points.

Are general drug manufacturer stocks a good buy now?

56.25% of general drug manufacturer stocks rated by analysts are a buy right now. On average, analysts expect general drug manufacturer stocks to rise by 10.35% over the next year.

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 33.39x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.